Somewhat Positive News Coverage Somewhat Unlikely to Affect Medidata Solutions (MDSO) Stock Price

Media headlines about Medidata Solutions (NASDAQ:MDSO) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Medidata Solutions earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.9766210317854 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Several equities research analysts have recently commented on the company. Jefferies Group LLC reissued a “hold” rating and issued a $78.00 price objective on shares of Medidata Solutions in a report on Tuesday, August 22nd. BidaskClub downgraded Medidata Solutions from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Citigroup Inc. reissued a “buy” rating and issued a $95.00 price objective (up previously from $94.00) on shares of Medidata Solutions in a report on Monday, July 24th. Zacks Investment Research downgraded Medidata Solutions from a “hold” rating to a “sell” rating in a report on Friday, July 21st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $90.00 price objective (up previously from $75.00) on shares of Medidata Solutions in a report on Friday, July 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the stock. Medidata Solutions currently has a consensus rating of “Buy” and an average price target of $82.91.

Shares of Medidata Solutions (NASDAQ MDSO) opened at 76.00 on Friday. The company has a market cap of $4.30 billion, a PE ratio of 122.78 and a beta of 1.81. The company has a 50-day moving average price of $74.70 and a 200-day moving average price of $69.72. Medidata Solutions has a 1-year low of $46.10 and a 1-year high of $85.92.

Medidata Solutions (NASDAQ:MDSO) last announced its earnings results on Tuesday, July 18th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.28 by $0.03. The company had revenue of $137.41 million for the quarter, compared to analysts’ expectations of $134.28 million. Medidata Solutions had a return on equity of 11.14% and a net margin of 7.07%. Medidata Solutions’s quarterly revenue was up 19.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.24 earnings per share. Equities research analysts expect that Medidata Solutions will post $1.28 earnings per share for the current fiscal year.

In other Medidata Solutions news, COO Michael L. Capone sold 5,000 shares of the business’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $74.53, for a total value of $372,650.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 5.80% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Medidata Solutions (MDSO) Stock Price” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/15/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-medidata-solutions-mdso-stock-price.html.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Insider Buying and Selling by Quarter for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply